Please login to the form below
MYSTIC trial
This page shows the latest MYSTIC trial news and features for those working in and with pharma, biotech and healthcare.
Innate Pharma and AstraZeneca take monalizumab into phase 3
The trial is set to begin in 2020, depending on regulatory and compliance approvals. ... However, the drug also failed to hit the first of two primary endpoints in the MYSTIC trial of Imfinzi plus AZ’s experimental CTLA4 inhibitor tremelimumab in
Latest news
-
AZ’s Imfinzi combo bombs again in non-small cell lung cancer
The same combination failed to move the needle in the MYSTIC trial, but signs of an improvement in a subgroup of patients with a particular cancer biomarker – high tumour mutational burden ... Meanwhile, the PEARL trial is pitting Imfinzi against
-
AZ to address Imfinzi setback, but sees potential with Tagrisso
During the MYSTIC trial, Imfinzi failed to hit the mark on progression-free survival and overall survival endpoints, but AstraZeneca said it would try the drug’s luck as a monotherapy ... However, AZ has confirmed that Imfinzi did demonstrate clinical
-
AZ still sees route to approval for Imfinzi in MYSTIC trial
expand and tweak the protocol of its ongoing NEPTUNE trial of Imfinzi with tremelimumab in first-line NSCLC that is due to generate results early next year. ... month and it is hard to explain why the duo performed worse than Imfinzi on its own in MYSTIC.
-
Is AstraZeneca looking for its next CEO?
The rumour has surfaced just days after the company confirmed that its immuno-oncology (IO) combination trial MYSTIC (twinning Imfinzi with CTLA4 candidate tremelimumab) failed to outperform chemo in overall survival
-
AZ’s MYSTIC survival data is in – and it’s a bust
Imfinzi failed to achieve OS improvement. AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and
More from news
Approximately 1 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
AstraZeneca’s oncology renaissance
The NELSON trial, which looked at screening in Europe, was presented at the recent World Conference on Lung Cancer. ... However, recent overall survival results from the MYSTIC trial, which studied Imfinzi with CTLA4 inhibitor tremelimumab, have just
-
AstraZeneca: building a new ‘open innovation’ pharma company
Open-minded culture. Like the new HQ’s construction, there have been setbacks – such as the setback to its Imfinzi tremelimumab immunotherapy combination in the MYSTIC lung cancer trial last year –
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- The Considered appoints Bam Zahraie as chief experience officer
- The impact of pharma congresses on HCPs – virtual and in person
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- A relentless commitment to neuroscience
- Putting the ovation into innovation: trends from ESMO
- Sanofi to acquire Provention Bio in deal worth $2.9bn
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Research Partnership
Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...
Latest intelligence
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
